References
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209–249. doi:https://doi.org/10.3322/caac.21660.
- Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, et al. Clinicopathologic features of advanced squamous NSCLC. J Thorac Oncol. 2016;11(9):1411–1422. doi:https://doi.org/10.1016/j.jtho.2016.05.024.
- Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thoracic Oncol. 2014;9(2):154–62. doi:https://doi.org/10.1097/JTO.0000000000000033.
- Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–7. doi:https://doi.org/10.1158/1078-0432.CCR-12-2246.
- Nagasaka M, Zhu VW, Lim SM, Greco M, Wu F, Ou SI. Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR + NSCLC. J Thoracic Oncol. 2021;16(5):740–63. doi:https://doi.org/10.1016/j.jtho.2020.11.028.
- Ahn M, Han J, Lee K, Kim S, Kim D, Lee Y, et al. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. The Lancet Oncol. 2019;20(12):1681–1690. doi:https://doi.org/10.1016/S1470-2045(19)30504-2.
- Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046–1061. doi:https://doi.org/10.1158/2159-8290.CD-14-0337.
- Yang JC, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, et al. Safety, efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-mutated advanced NSCLC: a multicenter, open-label, phase 1 trial. J Thoracic Oncol. 2020;15(12):1907–1918. doi:https://doi.org/10.1016/j.jtho.2020.09.001.
- Zhou C, Xie L, Liu W, Zhang L, Zhou S, Wang L, et al. Absorption, metabolism, excretion, and safety of [14C]almonertinib in healthy Chinese subjects . Ann Transl Med. 2021;9(10):867. doi:https://doi.org/10.21037/atm-21-1606.
- Shi Y, Zhang S, Hu X, Feng J, Ma Z, Zhou J, et al. Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation. J Thorac Oncol. 2020;15(6):1015–1026. doi:https://doi.org/10.1016/j.jtho.2020.01.010.
- Information NCfB. PubChem Compound Summary for CID 71496458, Osimertinib. 2021. https://pubchem.ncbi.nlm.nih.gov/compound/Osimertinib. Accessed Oct 19, 2021.
- Information NCfB. PubChem Compound Summary for CID 121280087, Almonertinib. 2021. https://pubchem.ncbi.nlm.nih.gov/compound/Almonertinib. Accessed Oct 19, 2021.
- Information NCfB. PubChem Compound Summary for CID 118861389, Alflutinib. 2021. https://pubchem.ncbi.nlm.nih.gov/compound/Alflutinib. Accessed Oct 19, 2021.
- Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–640. doi:https://doi.org/10.1056/NEJMoa1612674.
- Li J, Wang R, Gao J. Novel anticancer drugs approved in 2020. Drug Discov Ther. 2021;15(1):44–47. doi:https://doi.org/10.5582/ddt.2021.01013.
- Deeks ED. Furmonertinib: first approval. Drugs. 2021;81(15):1775–1780. doi:https://doi.org/10.1007/s40265-021-01588-w.
- Shi Y, Hu X, Zhang S, Lv D, Wu L, Yu Q, et al. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Lancet Respir Med. 2021;9(8):829–839. doi:https://doi.org/10.1016/S2213-2600(20)30455-0.
- Grande E, Harvey RD, You B, Batlle JF, Galbraith H, Sarantopoulos J, et al. Pharmacokinetic study of osimertinib in cancer patients with mild or moderate hepatic impairment. J Pharmacol Exp Ther. 2019;369(2):291–299. doi:https://doi.org/10.1124/jpet.118.255919.
- Brown K, Comisar C, Witjes H, Maringwa J, de Greef R, Vishwanathan K, et al. Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer. Br J Clin Pharmacol. 2017;83(6):1216–1226. doi:https://doi.org/10.1111/bcp.13223.
- Planchard D, Brown KH, Kim DW, Kim SW, Ohe Y, Felip E, et al. Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemother Pharmacol. 2016;77(4):767–776. doi:https://doi.org/10.1007/s00280-016-2992-z.
- Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–1699. doi:https://doi.org/10.1056/NEJMoa1411817.
- Dickinson PA, Cantarini MV, Collier J, Frewer P, Martin S, Pickup K, et al. Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor. Drug Metab Dispos. 2016;44(8):1201–1212. doi:https://doi.org/10.1124/dmd.115.069203.
- Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeño J, et al. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. Br J Clin Pharmacol. 2018;84(6):1156–1169. doi:https://doi.org/10.1111/bcp.13534.
- Liu L, Li W, Yang L, Guo ZT, Xue H, Xie NJ, et al. Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers. Acta Pharmacol Sin. 2022;43(4):1082–1090. doi:https://doi.org/10.1038/s41401-021-00710-8.
- Zhu S, Deng J, Tang Q, Heng J, Qu J, Chen Y, et al. A randomized, open, single-centre, crossed study of the effect of food on the pharmacokinetics of one oral dose of alflutinib mesylate tablets (AST2818) in healthy male subjects. Iran J Pharm Res. 2020;19:24–33.
- Liu XY, Guo ZT, Chen ZD, Zhang YF, Zhou JL, Jiang Y, et al. Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer. Acta Pharmacol Sin. 2020;41(10):1366–1376. doi:https://doi.org/10.1038/s41401-020-0389-3.
- Shanghai Allis Medical Technology Co. L. Jiahuangsuan Fumeitini Pian Yaopin Shuomingshu [Drug instruction of Furmonertinib Mesilate Tablets]. 2021. https://www.allist.com.cn/upload/202109/03/202109031700252412.pdf. Accessed Oct 19, 2021.
- Zhang Y, Zhang Y, Niu W, Ge X, Huang F, Pang J, et al. Experimental study of almonertinib crossing the blood-brain barrier in EGFR-mutant NSCLC brain metastasis and spinal cord metastasis models. Front Pharmacol. 2021;12:750031. doi:https://doi.org/10.3389/fphar.2021.750031.
- Colclough N, Chen K, Johnström P, Strittmatter N, Yan Y, Wrigley GL, et al. Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs. Clin Cancer Res. 2021;27(1):189–201. doi:https://doi.org/10.1158/1078-0432.CCR-19-1871.
- Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17(12):1643–52. doi:https://doi.org/10.1016/S1470-2045(16)30508-3.
- Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. JCO. 2017;35(12):1288–96. doi:https://doi.org/10.1200/JCO.2016.70.3223.
- Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020;31(11):1536–1544. doi:https://doi.org/10.1016/j.annonc.2020.08.2100.
- Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, et al. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM Study. J Clin Oncol. 2020;38(6):538–547. doi:https://doi.org/10.1200/JCO.19.00457.
- Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125. doi:https://doi.org/10.1056/NEJMoa1713137.
- Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol. 2018;29(3):687–693. doi:https://doi.org/10.1093/annonc/mdx820.
- Lu S, Wang Q, Zhang G. A multicenter, open-label, single-arm, phase II study: the third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO). Paper presented at: AACR Annual Meeting 2020.
- Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, OCN, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw. 2019;17(12):1464–1472. doi:https://doi.org/10.6004/jnccn.2019.0059.
- Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018;36(26):2702–2709. doi:https://doi.org/10.1200/JCO.2018.77.9363.
- Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(4):504–535. doi:https://doi.org/10.6004/jnccn.2017.0050.
- Wu YL, Herbst RS, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. ADAURA: phase III, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection. Clin Lung Cancer. 2018;19(4):e533–e536. doi:https://doi.org/10.1016/j.cllc.2018.04.004.
- Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711–23. doi:https://doi.org/10.1056/NEJMoa2027071.
- Cheng Y. Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations. 2020. https://clinicaltrials.gov/ct2/show/NCT04687241. Accessed Oct 12, 2021.
- He J. To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (FORWARD). 2021. https://clinicaltrials.gov/ct2/show/NCT04853342. Accessed Oct 12, 2021.
- Sun L, Guo YJ, Song J, Wang YR, Zhang SL, Huang LT, et al. Neoadjuvant EGFR-TKI therapy for EGFR-mutant NSCLC: a systematic review and pooled analysis of five prospective clinical trials. Front Oncol. 2020;10:586596. doi:https://doi.org/10.3389/fonc.2020.586596.
- Lv C, Ma Y, Feng Q, Lu F, Chi Y, Wu N, et al. Does neoadjuvant targeted therapy provide an opportunity for resectable EGFR-mutant lung cancer: a real-world retrospective study. J Thorac Dis. 2020;12(10):5324–5335. doi:https://doi.org/10.21037/jtd-20-1265.
- Tsuboi M, Weder W, Escriu C, Blakely C, He J, Dacic S, et al. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. Future Oncol. 2021;17(31):4045–4055. doi:https://doi.org/10.2217/fon-2021-0549.
- He J. Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC (ANSWER). 2020. https://clinicaltrials.gov/ct2/show/NCT04455594. Accessed Oct 12, 2021.
- Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, FLAURA Investigators, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50. doi:https://doi.org/10.1056/NEJMoa1913662.
- Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56(2):317–326. doi:https://doi.org/10.1016/j.jaad.2006.09.005.
- Wang J, Cheng X, Lu Y, Zhou B. A case report of toxic epidermal necrolysis associated with AZD-9291. Drug Des Devel Ther. 2018;12:2163–2167. doi:https://doi.org/10.2147/DDDT.S168248.
- Cui W, Cotter C, Sreter KB, Heelan K, Creamer D, Basu TN, et al. Case of fatal immune-related skin toxicity from sequential use of osimertinib after pembrolizumab: lessons for drug sequencing in never-smoking non-small-cell lung cancer. JCO Oncol Pract. 2020;16(12):842–844. doi:https://doi.org/10.1200/OP.20.00489.
- Andreyev J, Ross P, Donnellan C, Lennan E, Leonard P, Waters C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol. 2014;15(10):e447–460. doi:https://doi.org/10.1016/S1470-2045(14)70006-3.
- Van Sebille YZ, Gibson RJ, Wardill HR, Bowen JM. ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis. Cancer Treat Rev. 2015;41(7):646–52. doi:https://doi.org/10.1016/j.ctrv.2015.05.011.
- Yoshida H, Kim YH. Successful Osimertinib Rechallenge after Severe Osimertinib-Induced Hepatotoxicity. J Thoracic Oncol. 2017;12(5):e61–e63. doi:https://doi.org/10.1016/j.jtho.2017.01.026.
- Hirabayashi R, Fujimoto D, Satsuma Y, Hirabatake M, Tomii K. Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report. Invest New Drugs. 2018;36(5):952–954. doi:https://doi.org/10.1007/s10637-018-0608-7.
- Yamaguchi O, Kaira K, Kawasaki T, Mouri A, Hashimoto K, Shiono A, et al. Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation. Thorac Cancer. 2020;11(4):1045–1051. doi:https://doi.org/10.1111/1759-7714.13363.
- Ohe Y, Kato T, Sakai F, Kusumoto M, Endo M, Saito Y, et al. Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan. Jpn J Clin Oncol. 2020;50(8):909–919. doi:https://doi.org/10.1093/jjco/hyaa067.
- Jiang T, Luo Y, Wang B. Almonertinib-induced interstitial lung disease: A case report. Medicine (Baltimore)). 2021;100(3):e24393. doi:https://doi.org/10.1097/MD.0000000000024393.
- Gemma A, Kusumoto M, Sakai F, Endo M, Kato T, Saito Y, et al. Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with EGFR T790M-positive NSCLC treated with osimertinib in Japan. J Thoracic Oncol. 2020;15(12):1893–1906. doi:https://doi.org/10.1016/j.jtho.2020.08.025.
- Oshima Y, Tanimoto T, Yuji K, Tojo A. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol. 2018;4(8):1112–5. doi:https://doi.org/10.1001/jamaoncol.2017.4526.
- Mamesaya N, Kenmotsu H, Katsumata M, Nakajima T, Endo M, Takahashi T. Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody. Invest New Drugs. 2017;35(1):105–107. doi:https://doi.org/10.1007/s10637-016-0389-9.
- Schoenfeld AJ, Arbour KC, Rizvi H, Iqbal AN, Gadgeel SM, Girshman J, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol. 2019;30(5):839–44. doi:https://doi.org/10.1093/annonc/mdz077.
- Anand K, Ensor J, Trachtenberg B, Bernicker EH. Osimertinib-induced cardiotoxicity: a retrospective review of the FDA Adverse Events Reporting System (FAERS). JACC Cardiooncol. 2019;1(2):172–178. doi:https://doi.org/10.1016/j.jaccao.2019.10.006.
- Matsuura C, Kato T, Koyama K. Successful management of refractory Torsades De Pointes due to drug-induced long QT syndrome guided by point-of-care monitoring of ionized magnesium. Cureus. 2021;13(3):e13939. doi:https://doi.org/10.7759/cureus.13939.
- Schiefer M, Hendriks LEL, Dinh T, Lalji U, Dingemans AC. Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring. Eur J Cancer (Oxford, England: 1990). 2018;91:92–98. doi:https://doi.org/10.1016/j.ejca.2017.12.011.
- Pezhouman A, Singh N, Song Z, Nivala M, Eskandari A, Cao H, et al. Molecular basis of hypokalemia-induced ventricular fibrillation. Circulation. 2015;132(16):1528–1537. doi:https://doi.org/10.1161/CIRCULATIONAHA.115.016217.
- Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013–1022. doi:https://doi.org/10.1056/NEJMra032426.
- Roden DM. Predicting drug-induced QT prolongation and torsades de pointes. J Physiol. 2016;594(9):2459–2468. doi:https://doi.org/10.1113/JP270526.
- Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192–iv237. doi:https://doi.org/10.1093/annonc/mdy275.
- Liang W, Cai K, Chen C, Chen H, Fang W, Fu J, AME Thoracic Surgery Collaborative Group, et al. Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition). Transl Lung Cancer Res. 2019;8(6):1163–1173. doi:https://doi.org/10.21037/tlcr.2019.12.14.
- Koch AL, Vellanki PJ, Drezner N, Li X, Mishra-Kalyani PS, Shen YL, et al. FDA Approval Summary: Osimertinib for adjuvant treatment of surgically resected non-small cell lung cancer, a collaborative Project Orbis review. Clin Cancer Res. 2021;27(24):6638–6643. doi:https://doi.org/10.1158/1078-0432.CCR-21-1034.
- Russo A, Franchina T, Ricciardi G, Battaglia A, Picciotto M, Adamo V. Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new insights and future perspectives in this complex clinical scenario. IJMS. 2019;20(6):1431. doi:https://doi.org/10.3390/ijms20061431.
- Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, et al. EGFR Exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first- or third-generation TKIs. Clin Cancer Res. 2015;21(23):5305–13. doi:https://doi.org/10.1158/1078-0432.CCR-15-1046.
- Banno E, Togashi Y, Nakamura Y, Chiba M, Kobayashi Y, Hayashi H, et al. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor? Cancer Sci. 2016;107(8):1134–1140. doi:https://doi.org/10.1111/cas.12980.
- Passaro A, Mok T, Peters S, Popat S, Ahn M, de Marinis F. Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. J Thoracic Oncol. 2021;16(5):764–773. doi:https://doi.org/10.1016/j.jtho.2020.12.002.
- Shun L. Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment (ACTIVE). 2021. https://clinicaltrials.gov/ct2/show/NCT04882345. Accessed Oct 18, 2021.
- Ramalingam SS. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Presented at ESMO Congress 2018; 2018.
- Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 2018;4(11):1527–1534. doi:https://doi.org/10.1001/jamaoncol.2018.2969.
- Yu HA, Tian SK, Drilon AE, Borsu L, Riely GJ, Arcila ME, et al. Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. JAMA Oncol. 2015;1(7):982–984. doi:https://doi.org/10.1001/jamaoncol.2015.1066.
- Ho CC, Liao WY, Lin CA, Shih JY, Yu CJ, Yang JC. Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib. J Thoracic Oncol. 2017;12(3):567–572. doi:https://doi.org/10.1016/j.jtho.2016.11.2231.
- Ou SI, Agarwal N, Ali SM. High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. Lung Cancer (Amsterdam, Netherlands). 2016;98:59–61. doi:https://doi.org/10.1016/j.lungcan.2016.05.015.
- Ahn S, Hwang SH, Han J, Choi YL, Lee SH, Ahn JS, et al. Transformation to small cell lung cancer of pulmonary adenocarcinoma: clinicopathologic analysis of six cases. J Pathol Transl Med. 2016;50(4):258–263. doi:https://doi.org/10.4132/jptm.2016.04.19.
- Jia Y, Yun CH, Park E, Ercan D, Manuia M, Juarez J, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016;534(7605):129–32. doi:https://doi.org/10.1038/nature17960.
- To C, Jang J, Chen T, Park E, Mushajiang M, De Clercq DJH, et al. Single and dual targeting of mutant EGFR with an allosteric inhibitor. Cancer Discov. 2019;9(7):926–943. doi:https://doi.org/10.1158/2159-8290.CD-18-0903.
- Lei H, Fan S, Zhang H, Liu YJ, Hei YY, Zhang JJ, et al. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors. Eur J Med Chem. 2020;186:111888. doi:https://doi.org/10.1016/j.ejmech.2019.111888.
- Kashima K, Kawauchi H, Tanimura H, Tachibana Y, Chiba T, Torizawa T, et al. CH7233163 overcomes osimertinib-resistant EGFR-Del19/T790M/C797S mutation. Mol Cancer Ther. 2020;19(11):2288–2297. doi:https://doi.org/10.1158/1535-7163.MCT-20-0229.